The letters TTR getting knocked down by a heart from the aura of AMVUTTRA The letters TTR getting knocked down by a heart from the aura of AMVUTTRA

AMVUTTRA® DELIVERS

RAPID

KNOCKDOWN

The first and only silencer for both ATTR-CM and hATTR-PN, AMVUTTRA suppresses TTR* production at the source.1-4

Explore the data

*The primary source of TTR production is the liver, and TTR knockdown was first measured in the serum at 3 weeks in HELIOS-A and 6 weeks in HELIOS-B.5-7

 

Explore the efficacy data for ATTR‑CM

HELIOS-B Efficacy

 

Explore the efficacy data for hATTR‑PN

HELIOS-A Efficacy

 

Explore AMVUTTRA’s mechanism of action

How AMVUTTRA Works

 

Learn about the dosing and administration of AMVUTTRA

Dosing & Administration

 

Learn how to get your patients started with AMVUTTRA

Get Started With AMVUTTRA

 

Learn about patient support services

Access & Support

Over 13,000 patient-years of experience with AMVUTTRA worldwide5*

*Data reflect worldwide commercial use of AMVUTTRA as of December 2025.
ATTR-CM=cardiomyopathy of transthyretin-mediated amyloidosis; hATTR-PN=polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Stay informed

Receive more information about AMVUTTRA.

Connect with us

Find a treatment center

Locate a treatment center closest to your patients.

View the directory

UP NEXT: ATTR disease overview

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References

  1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. Fontana et al. N Engl J Med. 2025;392(1):33-44.
  3. Tomasoni et al. Front Cardiovasc Med. 2023;10:1154594.
  4. Williams et al. J Cardiothorac Vasc Anesth. 2024;38(7):1457-1459.
  5. Data on file. Alnylam Pharmaceuticals, Inc.
  6. Bezerra et al. Front Mol Neurosci. 2020;13:592644.
  7. Adams et al. Amyloid. 2023;30(1):18-26.
Alnylam Pharmaceuticals logo, click to visit corporate website

AMVUTTRA, Alnylam Assist, and their associated logos are trademarks of Alnylam Pharmaceuticals, Inc.

© 2026 Alnylam Pharmaceuticals, Inc. All rights reserved. This site is intended for US healthcare professionals. AMV-USA-00925